CurrentPremera BluecrossPolicy 1.01.525

Postsurgical Home Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis

Defines medical necessity criteria, documentation and coding for outpatient/home use of intermittent limb compression devices (IPC) for venous thromboembolism (VTE) prophylaxis after surgery, including orthopedic and select non-orthopedic procedures, plus contraindication and duration guidance.

Policy Summary

PayerPremera Bluecross

PolicyPostsurgical Home Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis

Policy CodePolicy 1.01.525

Change TypeAnnual reviewminor grammatical edits

Effective DateJun 1, 2026

Next Review Date

Key ActionDocument the surgical procedure and a contraindication to standard anticoagulant medications and state device use will be limited to 30 days when requesting home IPC coverage.

SourceLink

POLICY UPDATE CHANGES

Policy updated with literature review through January 13, 2026; minor grammatical edits; policy statements unchanged.

Interim and annual reviews between 2013 and 2026 made multiple edits to criteria wording, removed and added HCPCS codes over time, and renumbered policy (1.01.525 ↔ 1.01.28) with no substantive change to policy statements in recent years.

2Main covered surgery types (major orthopedic, major non-orthopedic)

3Orthopedic surgeries listed (THA/TKA/HFS)

3Non-orthopedic surgery examples specified

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

This policy (Policy 1.01.525, effective 2026-06-01, last reviewed 2026-05-11) defines coverage for postsurgical outpatient/home use of intermittent limb compression devices (IPC) for venous thromboembolism (VTE) prophylaxis. Postsurgical home IPC use is considered medically necessary when used after major orthopedic or selected major non-orthopedic surgeries if the individual has a documented contraindication to standard anticoagulant medications (high bleeding risk) and use is limited to 30 days post-surgery. The policy number is 1.01.525.

Thresholds and Key Criteria

Maximum covered durationUse limited to <= 30 days post-surgery

Required documentation on durationMedical record must state device will only be used for 30 days

ACCP bleeding risk classificationHigh risk = ≥2 bleeding risk factors (Low 0, Moderate 1, High ≥2) per ACCP table

Examples of ACCP bleeding risk factorsPrevious major bleeding; severe renal failure; concomitant antiplatelet agent; difficult-to-control surgical bleeding; extensive dissection; revision surgery; hemophilia or active liver disease (AAOS)

Caprini score risk levelsLow 1-2, Moderate 3-4, High ≥5 (Caprini Risk Assessment Model)

Guideline note on device type/durationACCP suggests portable, battery-operated devices and limited inpatient IPC duration (10–14 days for orthopedic); extended pharmacologic prophylaxis definitions differ

Medical Necessity Criteria

Coding

Covered HCPCSHCPCSCovered

E0676

Intermittent limb compression device (includes all accessories), not otherwise specified

Informational: sample FDA-cleared devicesmixed

AIROS 6	AIROS Medical, Inc. Sequential Compression Device; safe for home and hospital use
Plexus RP100	Alleva Medical Disposable Portable DVT Prevention Device; home or clinical settings; rechargeable battery
AeroDVx	Sun Scientific Inc System for hospital or outpatient use
VenaPro	InnovaMed Health Vascular Therapy System; battery-powered
Venowave VW5	Venowave battery-powered device strapped below the knee
ActiveCare+S.F.T.	Zimmer Biomet sequential pneumatic compression device; battery option
Restep DVT System	Stryker lightweight device with single-chamber pressure cuffs
Kendall SCD 700	CardinalHealth pneumatic compression device; clinic or home; battery option
PlasmaFlow	ManaMed portable system for home or clinical setting

FDA product code referencedmixed

JOW	FDA product code for pneumatic and peristaltic limb compression devices

Provider Actions & Billing

Documentation Required

Document surgery and contraindication to anticoagulants

Medical records must document the surgical procedure performed and a documented contraindication to standard anticoagulant medications (high bleeding risk) when requesting coverage for home intermittent limb compression devices.

Documentation Required

Document duration of device use

Record must state the device will only be used for 30 days post‑surgery. Claims for device use beyond 30 days post‑surgery are considered not medically necessary.

Billing Rule

Background & Evidence

Limb compression devices (intermittent pneumatic compression, IPC) reduce postoperative VTE risk and are widely used in-hospital; pharmacologic prophylaxis is the preferred approach in most surgical patients per national guidelines (ACCP, ACOG, ASH, AAOS). Mechanical prophylaxis is recommended when bleeding risk is high or when pharmacologic agents are contraindicated.

Evidence supports IPC use in the hospital setting and meta-analyses indicate benefit when IPC is added to pharmacologic prophylaxis during hospitalization, but there are no RCTs establishing incremental benefit of home IPC as an adjunct to anticoagulation after discharge. For patients with a contraindication to pharmacologic prophylaxis, limited randomized trial data and supporting studies indicate post-discharge home IPC is superior to no prophylaxis and likely improves VTE prevention when accompanied by postdischarge planning/support.

Evidence	Summary
RCT evidence for home IPC when anticoagulation contraindicated
One RCT and supporting trials indicate home IPC is superior to no prophylaxis in individuals with contraindication to pharmacologic prophylaxis; evidence sufficient to conclude improvement in net health outcome.
Evidence for IPC as adjunct to pharmacologic prophylaxis post-discharge
No RCTs assess incremental benefit of home IPC as adjunct to anticoagulation; evidence insufficient to determine net health outcome improvement.
Cochrane review (Kakkos et al.)
Combined intermittent pneumatic leg compression and pharmacologic prophylaxis for VTE prevention (CD005258).
American Society of Hematology 2019
Suggests intermittent compression devices over graduated compression stockings; combined prophylaxis favored with pharmacologic prophylaxis.

Definitions

Major orthopedic surgery: Total hip arthroplasty (THA/THR), total knee arthroplasty (TKA/TKR), or hip fracture surgery (HFS).

Contraindication to anticoagulants / high bleeding risk: Includes previous major bleeding, severe renal failure, concomitant antiplatelet agent, difficult-to-control surgical bleeding during the current procedure, extensive surgical dissection, revision surgery, hemophilia, active liver disease, and other factors per ACCP/AAOS guidance.

IPC (intermittent pneumatic compression device): Devices that apply intermittent limb compression; portable, battery-operated devices are preferred for home use per ACCP guidance.

Contraindication to standard anticoagulant medications: Includes intolerance to heparin preparations and surgical factors such as history of or difficult-to-control surgical bleeding during the current operative procedure, extensive surgical dissection, or revision surgery.

Device duration limit: Policy requires documentation that the device will be used for no more than 30 days post-surgery.

Medicare Determinations

Name	Type	Effective
Medicare National Coverage
NCD
none
National Coverage
NCD
no national coverage determination

Revision History

2026-05-11annual_reviewLatest

Annual review approved May 11, 2026; policy updated with literature review through January 13, 2026; minor grammatical edits; policy statements unchanged.

2013-03-11 to 2026-06-01history_summary

History shows multiple interim and annual reviews (2013–2026) with administrative and coding edits, occasional renumbering between policies 1.01.525 and 1.01.28, removal and addition of HCPCS codes, formatting and wording clarifications; policy intent and medical necessity statements remained substantively unchanged in recent years.